<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470-7330-14-S1-O18</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-O18</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Ovarian cancer: imaging in treatment selection and planning with FIGO update</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Sala</surname><given-names>Evis</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>O18</fpage><lpage>O18</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Sala; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Sala; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/O18"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title/><p>The International Federation of Gynecologists and Obstetricians (FIGO) has recently revised the staging of ovarian cancer [<xref ref-type="bibr" rid="B1">1</xref>]. It includes a revision of the stage III patients and allotment to stage IIIA1 is based on spread to the retroperitoneal lymph nodes without intraperitoneal dissemination, because an analysis of these patients indicates that their survival is significantly better than those who have intraperitoneal dissemination [<xref ref-type="bibr" rid="B1">1</xref>]. The FIGO staging system for ovarian cancer is surgically based. It does not formally include imaging but the FIGO committee encourages the use of imaging techniques if available to assess the important prognostic factors such as disease resectability and lymph node status.</p><p>The standard of care for patients with newly diagnosed advanced ovarian cancer has been comprehensive staging laparotomy and primary optimal surgical cytoreduction followed by adjuvant chemotherapy. However, the use of neoadjuvant chemotherapy followed by interval debulking surgery (IDS) as a suitable alternative is supported by multicenter randomized controlled trials [<xref ref-type="bibr" rid="B2">2</xref>]. Imaging is therefore of paramount importance in helping triage patients for appropriate management by accurately evaluating the extent and anatomical location of peritoneal spread, which in turn dictates the feasibility of cytoreductive surgery and predicts the likelihood of optimal primary cytoreduction. Optimal cytoreductive surgery (residual disease &#x0003c;1 cm) is a very strong predictor of survival, and even after the threshold for optimal cytoreduction has been reached, it is important to remove as much of the residual tumor as possible.</p><p>CT is the primary imaging modality used to stage ovarian cancer. It is complimentary to surgical staging identifying possible sites of unsuspected disease such as pelvic peritoneum, paraaortic nodes, diaphragm and chest [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. The thorax frequently harbors undiagnosed pleural disease at the time of the initial diagnosis which is likely to affect survival even in cases of optimal debulking [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Accurate imaging helps guide the surgeon to areas of disease that may be difficult to identify surgically. Relative criteria for non-optimally resectable disease have been developed [<xref ref-type="bibr" rid="B7">7</xref>]. They include lymph node enlargement above the renal hilum, presence of abdominal wall invasion, parenchymal liver and subcapsular liver metastases, peritoneal implants of &#x0003e;2 cm along the diaphragm, lesser sac, porta hepatis, intersegmental fissure, gall bladder fossa, gastrosplenic, gastrohepatic ligament and small bowel mesentery. However, it is important to realize that these criteria may vary and will depend on the aggressiveness of the surgical procedure and on the performance status of the patient. Therefore, they should only be used as a basis for a multidisciplinary consensus. It is important to note that upper abdominal disease and pleural metastases can be surgically resected, but this requires careful planning as it involves a team of surgeons (e.g. liver surgeons for hepatic resection). There has been a growing awareness of the potential of diffusion weighted magnetic resonance imaging (DW-MRI) in improving the mapping of the extent of ovarian cancer [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. There is also growing evidence that FDG-PET/CT may play a role in pre-operative staging of patients with advance ovarian cancer [<xref ref-type="bibr" rid="B10">10</xref>].</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Prat</surname><given-names>J</given-names></name><article-title>Staging classification for cancer of the ovary, fallopian tube, and peritoneum</article-title><source>Int J Gynecol Obstet</source><year>2013</year><volume>124</volume><issue>1</issue><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.ijgo.2013.10.001</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Trope</surname><given-names>CG</given-names></name><name><surname>Amant</surname><given-names>F</given-names></name><etal/><article-title>Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>943</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908806</pub-id><?supplied-pmid 20818904?><pub-id pub-id-type="pmid">20818904</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Coakley</surname><given-names>FV</given-names></name><article-title>Staging ovarian cancer: role of imaging</article-title><source>Radiol Clin North Am</source><year>2002</year><volume>40</volume><fpage>609</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/S0033-8389(01)00012-4</pub-id><?supplied-pmid 12117196?><pub-id pub-id-type="pmid">12117196</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Coakley</surname><given-names>FV</given-names></name><name><surname>Choi</surname><given-names>PH</given-names></name><name><surname>Gougoutas</surname><given-names>CA</given-names></name><etal/><article-title>Peritoneal metastases: detection with spiral CT in patients with ovarian cancer</article-title><source>Radiology</source><year>2002</year><volume>223</volume><fpage>495</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1148/radiol.2232011081</pub-id><?supplied-pmid 11997559?><pub-id pub-id-type="pmid">11997559</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Chi</surname><given-names>DS</given-names></name><name><surname>Abu-Rustum</surname><given-names>NR</given-names></name><name><surname>Sonoda</surname><given-names>Y</given-names></name><etal/><article-title>The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions</article-title><source>Gynecol Oncol</source><year>2004</year><volume>94</volume><fpage>307</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2004.04.027</pub-id><?supplied-pmid 15297166?><pub-id pub-id-type="pmid">15297166</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Mironov</surname><given-names>O</given-names></name><name><surname>Ishill</surname><given-names>NM</given-names></name><name><surname>Mironov</surname><given-names>S</given-names></name><etal/><article-title>eural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival</article-title><source>Radiology</source><year>2011</year><volume>258</volume><fpage>776</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1148/radiol.10100162</pub-id><?supplied-pmid 21193598?><pub-id pub-id-type="pmid">21193598</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Qayyum</surname><given-names>A</given-names></name><name><surname>Coakley</surname><given-names>FV</given-names></name><name><surname>Westphalen</surname><given-names>AC</given-names></name><name><surname>Hricak</surname><given-names>H</given-names></name><name><surname>Okuno</surname><given-names>WT</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><article-title>Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer</article-title><source>Gynecol Oncol</source><year>2005</year><volume>96</volume><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2004.06.054</pub-id><?supplied-pmid 15661212?><pub-id pub-id-type="pmid">15661212</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Matsusue</surname><given-names>E</given-names></name><name><surname>Kanasaki</surname><given-names>Y</given-names></name><etal/><article-title>Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging</article-title><source>Eur Radiol</source><year>2008</year><volume>18</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s00330-007-0732-9</pub-id><?supplied-pmid 17701040?><pub-id pub-id-type="pmid">17701040</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Michielsen</surname><given-names>K</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Op de beeck</surname><given-names>K</given-names></name><etal/><article-title>Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT</article-title><source>Eur Radiol</source><year>2014</year><volume>24</volume><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1007/s00330-013-3083-8</pub-id><?supplied-pmid 24322510?><pub-id pub-id-type="pmid">24322510</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Kitajima</surname><given-names>K</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Yamasaki</surname><given-names>E</given-names></name><etal/><article-title>Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2008</year><volume>35</volume><fpage>1912</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1007/s00259-008-0890-2</pub-id><?supplied-pmid 18682935?><pub-id pub-id-type="pmid">18682935</pub-id></mixed-citation></ref></ref-list></back></article>
